CDC headquarters in Atlanta
Elijah Nouvelage | Bloomberg by way of Getty Images
A key U.S. Centers for Disease Control and Prevention panel voted unanimously to advocate Pfizer–BioNTech‘s Covid-19 vaccine for people 16 years and older on Saturday, clearing one other pivotal hurdle for the drug earlier than vaccinations start within the coming days.
The CDC’s Advisory Committee on Immunization Practices, an outdoor group of medical consultants that advises the company, voted 11 to zero advocate the vaccine for use in people 16 and older below the Food and Drug Administrations emergency authorization. Three members recused themselves attributable to conflicts.
On Dec. 1, the group voted 13-1 to offer health-care employees and long-term care facility residents the primary vaccine doses as soon as cleared for public use. The ACIP’s emergency assembly, which was pushed from Sunday to Saturday, adopted the FDA’s choice to problem Pfizer’s vaccine an emergency use authorization Friday night.
This is a creating story. Please examine again later for updates.